Monday, February 16, 2026 2/16/2026

Function of Long Non-Coding RNA MD1 in Leiomyoma Pathogenesis

Award Number: R03HD101852
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2021
PERIOD OF PERFORMANCE END DATE: 02/29/2024

Group Awards By:

View Award Description

Function of Long Non-Coding RNA MD1 in Leiomyoma Pathogenesis - Uterine leiomyoma (fibroids) develop during reproductive years in over 70% of women; however, their etiology remains unknown. Our group has identified two miRNAs, miR-200c and miR-29c, which are critical to regulation of genes functionally associated with cell cycle, cellular transformation, inflammation and extracellular matrix accumulation and thus of great significance to fibroid pathogenesis. Our recent findings using next generation sequencing provided a comprehensive profile of non-coding RNAs including long non- coding RNAs (lncRNAs) as well as novel groups of small non-coding RNAs (sncRNAs). Our preliminary findings here have identified aberrant expression of linc-MD1 and miR-135 family in fibroids and thus the impetus for this proposal. Using qRT-PCR we detected markedly reduced levels of linc-MD1 while significantly higher expression of miR-135 family in leiomyomas. The sequences of the linc-MD1 and our preliminary data suggest that linc-MD1 can act as miRNA sponge for miR-135 family (miR-135a/-135b) in leiomyoma smooth muscle cells. Therefore, based on this preliminary data we hypothesize that leiomyoma as compared to myometrium displays reduced expression of linc-MD1 which through a miRNA-guided mechanism involving miR-135 regulates the expression of specific target genes functionally associated with Wnt/β-catenin signaling pathway which is known to be central to leiomyoma pathogenesis. To test our core hypothesis we propose 2 specific aims. In Aim 1 we will determine the interaction between linc-MD1 and miR-135 family by RNA immunoprecipitation and RNA pull-down assay. We will over or under express linc-MD1 in LSMC or MSMC spheroid cells and determine its effect on miR-135 family and its downstream target genes namely GSK3β and APC which are known to regulate β-Catenin degradation. In these experiments β-Catenin, its phosphorylated form and its nuclear localization will be determined in response to overexpression and knockdown studies in vitro. To establish the clinical relevance and therapeutic potential of linc-MD1 in Aim 2 we will determine the effect of linc-MD1 overexpression in leiomyoma cells on fibroid progression in a leiomyoma animal model. This translational proposal addresses a significant gap in knowledge on the role of a novel lncRNA-miRNA network in the pathogenesis of fibroids which is a priority area of investigation for NIH, and could potentially be targeted for therapeutic purposes for fibroids.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER	1124 W CARSON ST BLDG MRL	TORRANCE	CA	90502	LOS ANGELES	USA	Child Health and Human Development Extramural Research	000	2	7/3/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $77,050 )
2022	2022	LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER	1124 WEST CARSON ST.	TORRANCE	CA	90502	LOS ANGELES	USA	Child Health and Human Development Extramural Research	000	2	4/8/2022	NON-COMPETING CONTINUATION	$69,345
2022	2022	LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER	1124 WEST CARSON ST.	TORRANCE	CA	90502	LOS ANGELES	USA	Child Health and Human Development Extramural Research	001	2	4/25/2022	NON-COMPETING CONTINUATION	$7,705
														Subtotal = $77,050

Issue Date FY: 2021 ( Subtotal = $77,050 )
2021	2021	LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER	1124 WEST CARSON ST.	TORRANCE	CA	90502	LOS ANGELES	USA	Child Health and Human Development Extramural Research	000	1	3/11/2021	NEW	$77,050
														Subtotal = $77,050

Grand Total All Awards = $154,100

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Function of Long Non-Coding RNA MD1 in Leiomyoma Pathogenesis

Award Number: R03HD101852

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2021

PERIOD OF PERFORMANCE END DATE: 02/29/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer